At Alturos, we are dedicated to transforming the lives of millions affected by neurodegenerative diseases. By shifting the focus from symptomatic relief to core neuroprotection, we aim to intercept disease progression before irreversible damage occurs.
A Necessary Shift in the Therapeutic Paradigm
The recent introduction of disease-modifying therapies marks a historic milestone in Alzheimer’s research, confirming that targeting the underlying biology of the disease can yield clinical results. However, neurodegeneration is a complex, multifaceted process, and a significant unmet medical need remains for diverse therapeutic strategies.
Our Solution: Active Neuroprotection
At Alturos, we believe that addressing the full spectrum of the disease requires expanding the therapeutic toolkit. Our research focuses on the earliest toxic triggers, protein oligomers, that play a critical role in driving synaptic loss and neuronal death. Our goal is to translate these biological insights into convenient, oral and effective therapies fighting against neurodegenerative diseases, that can reach a broader range of patients and provide a vital new pillar, complementing the evolving landscape of neurodegenerative care.
Already demonstrating clear clinical benefits in preclinical in vivo models, our innovative small molecule candidates open up entirely new avenues in the Alzheimer's Disease field. Because they are designed to be safe and are conveniently dosed orally, they pave the way for sustainable, long-term chronic treatment and innovative combination therapies.
Driven by Scientific Rigour and Experience
We have the scientific foundation and the leadership required to bring this bold vision to the clinic. Built upon a pre-clinical drug discovery program acquired through an asset deal with Lakefront Biotherapeutics, our work is supported by a robust in vitro and in vivo efficacy data package.
As we ready ourselves for IND-enabling studies, Alturos Therapeutics is guided by an experienced management team with a proven track record in neurodegenerative drug development across Lakefront Biotherapeutics, Treeway, and 3D-PharmXchange. We are entirely dedicated to delivering the next generation of therapeutics to the patients who need them most.
As CEO and CSO of Alturos, Jan leverages more than 25 years of biotech leadership, including an extensive tenure at Lakefront Biotherapeutics, where he served as VP of Site Operations and Discovery Site Head. Jan was the program lead for the main Alzheimer’s drug discovery asset at Lakefront Biotherapeutics, bringing firsthand experience
As CEO and CSO of Alturos, Jan leverages more than 25 years of biotech leadership, including an extensive tenure at Lakefront Biotherapeutics, where he served as VP of Site Operations and Discovery Site Head. Jan was the program lead for the main Alzheimer’s drug discovery asset at Lakefront Biotherapeutics, bringing firsthand experience in the discovery of novel neurodegenerative therapies. His broad expertise in drug discovery program management and operations now drives Alturos’ mission and scientific strategy.
As CDO of Alturos, Ronald leverages over 25 years of pharmaceutical and biotech experience from leading organisations, including J&J, Tibotec, uniQure, and Lakefront Biotherapeutics. A clinical pharmacologist, serial entrepreneur, and inventor, he has a proven track record of advancing complex therapeutics, highlighted by his continued wo
As CDO of Alturos, Ronald leverages over 25 years of pharmaceutical and biotech experience from leading organisations, including J&J, Tibotec, uniQure, and Lakefront Biotherapeutics. A clinical pharmacologist, serial entrepreneur, and inventor, he has a proven track record of advancing complex therapeutics, highlighted by his continued work at 3D-PharmXchange and as CDO of Treeway. Specializing in biomarker development, Ronald brings critical clinical execution expertise to Alturos, having steered programs through Phase 3 for ALS and Phase 2a for Alzheimer’s Disease in the past.
As COO and CBO, Inez leverages over 20 years of experience at J&J, Astellas, and Kinesis Pharma to drive Alturos’ commercial and operational strategy. A drug development expert and serial entrepreneur, she founded 3D-PharmXchange and served as CEO of Treeway, raising over €50M in capital and securing major licensing deals. Inez is a Fello
As COO and CBO, Inez leverages over 20 years of experience at J&J, Astellas, and Kinesis Pharma to drive Alturos’ commercial and operational strategy. A drug development expert and serial entrepreneur, she founded 3D-PharmXchange and served as CEO of Treeway, raising over €50M in capital and securing major licensing deals. Inez is a Fellow of the Netherlands Academy of Engineers and an active board member, combining high-level technical expertise with a proven track record of scaling biotech ventures.
As non-clinical project manager, Marnix is our newest member. He is completing his internship in pharmaceutical sciences with a business specialisation. Managing the early business development for Alturos, his work is vital in creating a stable foundation on which the future of Alturos will be built. Marnix brings fresh perspectives into
As non-clinical project manager, Marnix is our newest member. He is completing his internship in pharmaceutical sciences with a business specialisation. Managing the early business development for Alturos, his work is vital in creating a stable foundation on which the future of Alturos will be built. Marnix brings fresh perspectives into the seasoned management team of Alturos and bridges the gap between science and business. Marnix has previously worked on a 9-month research internship at the LACDR, where he worked on utilising LLM's in early stage testing of cardio- and hepatotoxicity for novel compounds.
We welcome inquiries from prospective collaborators, investors, and anyone interested in our work. You may use the contact form or email us directly.
Copyright © 2026 Alturos Therapeutics - All rights reserved